Harrow (NASDAQ:HROW) Now Covered by Analysts at BTIG Research

BTIG Research began coverage on shares of Harrow (NASDAQ:HROW) in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $62.00 target price on the stock.

Several other analysts have also recently weighed in on HROW. HC Wainwright raised their price target on Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a report on Monday, May 12th. William Blair started coverage on Harrow in a report on Tuesday. They set an “outperform” rating on the stock. Finally, B. Riley decreased their price objective on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $61.40.

Harrow Stock Performance

NASDAQ:HROW opened at $31.16 on Thursday. The business’s 50-day moving average price is $26.00 and its two-hundred day moving average price is $29.77. Harrow has a twelve month low of $16.87 and a twelve month high of $59.23. The stock has a market cap of $1.14 billion, a P/E ratio of -33.15 and a beta of 0.40. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $47.83 million during the quarter, compared to analysts’ expectations of $57.00 million. As a group, equities analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Harrow

Large investors have recently modified their holdings of the company. Barclays PLC raised its holdings in shares of Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company’s stock valued at $2,365,000 after buying an additional 39,506 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Harrow by 89.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock worth $2,078,000 after purchasing an additional 29,262 shares during the period. Northern Trust Corp increased its stake in Harrow by 7.5% in the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company’s stock worth $10,705,000 after purchasing an additional 22,266 shares during the period. Tower Research Capital LLC TRC increased its stake in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after purchasing an additional 1,462 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Harrow by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock worth $2,900,000 after purchasing an additional 6,690 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.